Drugs / BT-114143
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07169214 | Oct 2024 → Sep 2025 overdue | — | ScinnoHub Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07169240 | Feb 2023 → Apr 2024 | — | ScinnoHub Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07127042 | Aug 2025 → Dec 2026 expected | — | ScinnoHub Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT-114143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07169240 ↗ |
| Route | Intravenous | “Intravenous infusion of BT-114143 Injection” NCT07127042 ↗ |